The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Advances Amgen's mission to serve patients with rare disease medicines
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
With an annual revenue of about $500 million, Spectrum will become part of the Industrial Solutions line of business within the Electronics & Industrial segment
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Subscribe To Our Newsletter & Stay Updated
